Dr. Bruce Eric Sands, MD

Dr. Sands practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Sands' NPI, 1093706665, was assigned on November 2, 2005. Dr. Sands graduated from Boston University School of Medicine in 1987. Dr. Sands holds New York license 256919.

Dr. Sands' primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Sands also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Sands' primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Sands to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sands practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Sands' primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Sands is licensed in New York.

CMS data shows 156 Medicare services from Dr. Sands across 5 procedure codes in 2024, for 119 Medicare patients. Medicare paid $13,364 for them.

CMS counts 119 Medicare patients who saw Dr. Sands in 2024. The largest group is 65 to 74, with 56 patients. 70% of them have high cholesterol, and 62% have high blood pressure. 24% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sands' median patient age at 44, with 44% women.

In 2024, Dr. Sands wrote 238 Medicare Part D claims for 45 patients. 57% of them were for generic drugs. CMS names the drug for 100 of them, across 6 drugs with 11 or more claims each, at $915,441 in total drug cost. In 2023, CMS named 88 claims across 5 drugs.

Dr. Sands accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sands as offering telehealth. CMS counts 14 procedures of colonoscopy by Dr. Sands, more than 44% of the clinicians it reports for that procedure.

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 259 papers to Dr. Sands, published from 2010 to 2025. 2024 was the busiest year, with 24. The most frequent topics are Colitis, Ulcerative, Crohn Disease and Inflammatory Bowel Diseases. Dr. Sands has published most often in Inflamm Bowel Dis. Dr. Sands' most frequent co-authors are William J. Sandborn, MD, Bruce E. Sands, MD and Edward Vincent Loftus, MD.

Dmand AI links Dr. Sands to 5 clinical trials. Conditions studied include Crohn Disease, Inflammatory Bowel Diseases and Abdominal Pain. Icahn School of Medicine at Mount Sinai sponsors the most, 2. Open Payments lists research payments to Dr. Sands that name 2 trials.

CMS Open Payments shows 812 general payments to Dr. Sands from 37 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Pfizer Inc. paid the most, $261,252. It also lists 126 research payments totaling $141,351 from 2017 to 2025, naming 2 clinical trials.

Dr. Sands graduated from Boston University School of Medicine in 1987.